New program tracks rare side effects of schizophrenia injection
NCT ID NCT01088386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program monitors 4000 people with schizophrenia who receive Zyprexa Relprevv, a long-acting injection. The goal is to track and reduce the risk of a rare but serious reaction called post-injection delirium/sedation syndrome (PDSS). Researchers will record how often PDSS happens and look for possible risk factors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olanzapine pamoate (Zyprexa Relprevv)
- What this could lead to
- If successful, this program could help make Zyprexa Relprevv safer by identifying risk factors and reducing rare but serious post-injection reactions.
- What could go wrong
- This is an observational safety program, not a test of whether the drug works. It may not change how the drug is used, and rare events may still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
United BioSource Corporation
Blue Bell, Pennsylvania, 19422, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?